A Multicenter Study of 239 Patients Aged Over 70 Years With Diffuse Large B-Cell Lymphoma in China
Conclusion: Our study presents the clinical profiles and survival outcomes of elderly patients with DLBCL in China. Treatment of these patients requires careful evaluation of toxicities and benefits. To this end, a prognosis model, such as comprehensive geriatric assessment, is required in clinical practice to optimally manage elderly patients with DLBCL.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Chemotherapy | China Health | Drugs & Pharmacology | Geriatrics | Hematology | Lymphoma | Rituxan | Study | Toxicology